Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Key Research Features Triple-hormone receptor agonist GIP + GLP-1 + Glucagon (GCGR) Tuned potency hierarchy across all three receptor targets C20 fatty diacid moiety albumin binding, ~6-day half-life in research models Simultaneous energy intake and energy expenditure pathway modeling 99% HPLC-verified purity LC-MS sequence and molecular weight identity confirmed Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, Retatrutide should be: Stored at 20C in a tightly sealed container Protected from light and moisture Reconstituted in sterile or bacteriostatic water Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information Currently an Investigational New Drug (IND) under active Phase 3 clinical investigation (TRIUMPH and TRANSCEND trial series) Not FDA-approved for any therapeutic indication as of current date Prohibited by the World Anti-Doping Agency (WADA) under S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics Supplied strictly as a Research Use Only (RUO) material Why Choose Summit Pep Labs
A safe obesity treatment that slows digestion and curbs cravings Extenatide was the very first GLP-1-mimicking drug
A study coming out in the next month or so is expected to show a 20% reduction in heart attacks, strokes, and death from a cardiovascular cause
This is where glutathione steps in binding to these toxins and escorting them safely out in Phase II
It takes approximately 4 to 5 weeks of consistent daily dosing to reach steady-state blood levels
Sykora, M., Diedler, J., Rupp, A., Turcani, P
US$ 21.79
US$ 26.40
US$ 23.44
US$ 23.52
US$ 28.39
